" /> " />

Pfizer Earnings Estimate

PFE Stock  USD 27.75  0.03  0.11%   
The next projected EPS of Pfizer is estimated to be 0.54 with future projections ranging from a low of 0.34 to a high of 0.76. Pfizer's most recent 12-month trailing earnings per share (EPS TTM) is at 0.37. Please be aware that the consensus of earnings estimates for Pfizer Inc is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Pfizer is projected to generate 0.54 in earnings per share on the 31st of March 2024. Pfizer earnings estimates module stress-tests analyst consensus about projected Pfizer Inc EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. Many public companies, such as Pfizer, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Pfizer's earnings estimates, investors can diagnose different trends across Pfizer's analyst sentiment over time as well as compare current estimates against different timeframes. At present, Pfizer's Gross Profit Margin is projected to slightly decrease based on the last few years of reporting.
  
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census.

Pfizer Earnings Estimation Breakdown

The calculation of Pfizer's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Pfizer is estimated to be 0.54 with the future projection ranging from a low of 0.34 to a high of 0.76. Please be aware that this consensus of annual earnings estimates for Pfizer Inc is based on EPS before non-recurring items and includes expenses related to employee stock options.
Last Reported EPS
0.1
0.34
Lowest
Expected EPS
0.54
0.76
Highest

Pfizer Earnings Projection Consensus

Suppose the current estimates of Pfizer's value are higher than the current market price of the Pfizer stock. In this case, investors may conclude that Pfizer is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Pfizer's stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyLast Reported EPSEstimated EPS for 31st of March 2024Current EPS (TTM)
2267.46%
0.1
0.54
0.37

Pfizer Earnings History

Earnings estimate consensus by Pfizer Inc analysts from Wall Street is used by the market to judge Pfizer's stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Pfizer's upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.

Pfizer Quarterly Gross Profit

5.66 Billion

At present, Pfizer's Price Earnings Ratio is projected to increase significantly based on the last few years of reporting. The current year's Common Stock Shares Outstanding is expected to grow to about 6.3 B. The current year's Net Income Applicable To Common Shares is expected to grow to about 37.9 B.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Pfizer's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
26.3427.7529.16
Details
Intrinsic
Valuation
LowRealHigh
24.9833.1734.58
Details
Naive
Forecast
LowNextHigh
26.1427.5528.96
Details
25 Analysts
Consensus
LowTargetHigh
35.1938.6742.92
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Pfizer. Your research has to be compared to or analyzed against Pfizer's peers to derive any actionable benefits. When done correctly, Pfizer's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Pfizer Inc. Note that many institutional investors and large investment bankers can move markets due to the volume of Pfizer assets they manage. They also follow analysts to some degree and often drive overall investor sentiments towards Pfizer. With so many stockholders watching consensus numbers, the difference between actual and projected earnings is one of the most critical factors driving Pfizer's stock price in the short term.

Pfizer Earnings per Share Projection vs Actual

Actual Earning per Share of Pfizer refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Pfizer Inc predict the company's earnings will be in the future. The higher the earnings per share of Pfizer, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Pfizer Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Pfizer, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Pfizer should always be considered in relation to other companies to make a more educated investment decision.

Pfizer Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Pfizer's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-01-30
2023-12-31-0.220.10.32145 
2023-10-31
2023-09-30-0.34-0.170.1750 
2023-08-01
2023-06-300.570.670.117 
2023-05-02
2023-03-310.981.230.2525 
2023-01-31
2022-12-311.051.140.09
2022-11-01
2022-09-301.391.780.3928 
2022-07-28
2022-06-301.782.040.2614 
2022-05-03
2022-03-311.471.670.213 
2022-02-08
2021-12-310.871.080.2124 
2021-11-02
2021-09-301.091.340.2522 
2021-07-28
2021-06-300.971.070.110 
2021-05-04
2021-03-310.770.930.1620 
2021-02-02
2020-12-310.480.42-0.0612 
2020-10-27
2020-09-300.710.720.01
2020-07-28
2020-06-300.660.780.1218 
2020-04-28
2020-03-310.730.80.07
2020-01-28
2019-12-310.580.55-0.03
2019-10-29
2019-09-300.620.750.1320 
2019-07-29
2019-06-300.750.80.05
2019-04-30
2019-03-310.750.850.113 
2019-01-29
2018-12-310.630.640.01
2018-10-30
2018-09-300.750.780.03
2018-07-31
2018-06-300.740.810.07
2018-05-01
2018-03-310.740.770.03
2018-01-30
2017-12-310.560.620.0610 
2017-10-31
2017-09-300.640.670.03
2017-08-01
2017-06-300.660.670.01
2017-05-02
2017-03-310.670.690.02
2017-01-31
2016-12-310.50.47-0.03
2016-11-01
2016-09-300.620.61-0.01
2016-08-02
2016-06-300.620.640.02
2016-05-03
2016-03-310.550.670.1221 
2016-02-02
2015-12-310.520.530.01
2015-10-27
2015-09-300.510.60.0917 
2015-07-28
2015-06-300.520.560.04
2015-04-28
2015-03-310.490.510.02
2015-01-27
2014-12-310.530.540.01
2014-10-28
2014-09-300.550.570.02
2014-07-29
2014-06-300.570.580.01
2014-05-05
2014-03-310.550.570.02
2014-01-28
2013-12-310.520.560.04
2013-10-29
2013-09-300.560.580.02
2013-07-30
2013-06-300.550.560.01
2013-04-30
2013-03-310.550.54-0.01
2013-01-29
2012-12-310.440.470.03
2012-11-01
2012-09-300.530.530.0
2012-07-31
2012-06-300.540.620.0814 
2012-05-01
2012-03-310.560.580.02
2012-01-31
2011-12-310.470.50.03
2011-11-01
2011-09-300.560.620.0610 
2011-08-02
2011-06-300.590.60.01
2011-05-03
2011-03-310.590.60.01
2011-02-01
2010-12-310.460.470.01
2010-11-02
2010-09-300.510.540.03
2010-08-03
2010-06-300.520.620.119 
2010-05-04
2010-03-310.530.60.0713 
2010-02-03
2009-12-310.50.49-0.01
2009-10-20
2009-09-300.480.510.03
2009-07-22
2009-06-300.470.480.01
2009-04-28
2009-03-310.490.540.0510 
2009-01-26
2008-12-310.590.650.0610 
2008-10-21
2008-09-300.60.620.02
2008-07-23
2008-06-300.540.550.01
2008-04-17
2008-03-310.660.61-0.05
2008-01-23
2007-12-310.470.520.0510 
2007-10-18
2007-09-300.530.580.05
2007-07-18
2007-06-300.50.42-0.0816 
2007-04-20
2007-03-310.570.680.1119 
2007-01-22
2006-12-310.420.430.01
2006-10-19
2006-09-300.450.540.0920 
2006-07-20
2006-06-300.480.50.02
2006-04-19
2006-03-310.530.610.0815 
2006-01-19
2005-12-310.420.510.0921 
2005-10-20
2005-09-300.480.510.03
2005-07-20
2005-06-300.440.460.02
2005-04-19
2005-03-310.530.540.01
2005-01-19
2004-12-310.590.58-0.01
2004-10-20
2004-09-300.540.550.01
2004-07-21
2004-06-300.470.470.0
2004-04-20
2004-03-310.510.520.01
2004-01-22
2003-12-310.510.530.02
2003-10-22
2003-09-300.440.470.03
2003-07-25
2003-06-300.290.30.01
2003-04-22
2003-03-310.440.450.01
2003-01-22
2002-12-310.470.480.01
2002-10-16
2002-09-300.390.390.0
2002-07-15
2002-06-300.320.330.01
2002-04-17
2002-03-310.390.390.0
2002-01-23
2001-12-310.340.340.0
2001-10-17
2001-09-300.330.340.01
2001-07-17
2001-06-300.290.30.01
2001-04-18
2001-03-310.310.330.02
2001-01-24
2000-12-310.270.270.0
2000-10-24
2000-09-300.260.270.01
2000-07-24
2000-06-300.220.230.01
2000-04-18
2000-03-310.250.280.0312 
2000-01-18
1999-12-310.230.250.02
1999-10-19
1999-09-300.210.230.02
1999-07-19
1999-06-300.170.190.0211 
1999-04-15
1999-03-310.210.210.0
1999-01-19
1998-12-310.170.180.01
1998-10-13
1998-09-300.190.17-0.0210 
1998-07-09
1998-06-300.150.170.0213 
1998-04-14
1998-03-310.180.180.0
1998-01-20
1997-12-310.140.140.0
1997-10-14
1997-09-300.150.150.0
1997-07-15
1997-06-300.120.120.0
1997-04-15
1997-03-310.160.160.0
1997-01-16
1996-12-310.130.130.0
1996-10-14
1996-09-300.130.130.0
1996-07-17
1996-06-300.10.10.0
1996-04-16
1996-03-310.130.140.01
1996-01-17
1995-12-310.110.110.0
1995-10-15
1995-09-300.110.110.0

About Pfizer Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Pfizer earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Pfizer estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Pfizer fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for 2024
Retained Earnings118.4 B124.3 B
Retained Earnings Total Equity118.4 B87 B
Price Earnings Ratio 76.67  80.50 
Price Earnings To Growth Ratio(0.82)(0.78)

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pfizer Inc using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
When determining whether Pfizer Inc is a strong investment it is important to analyze Pfizer's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pfizer's future performance. For an informed investment choice regarding Pfizer Stock, refer to the following important reports:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census.
Note that the Pfizer Inc information on this page should be used as a complementary analysis to other Pfizer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Pfizer Stock analysis

When running Pfizer's price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
CEOs Directory
Screen CEOs from public companies around the world
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Global Correlations
Find global opportunities by holding instruments from different markets
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Is Pfizer's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.76)
Dividend Share
1.64
Earnings Share
0.37
Revenue Per Share
10.366
Quarterly Revenue Growth
(0.41)
The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pfizer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.